Dercos Fortifying Treatment 5 for Anti-Hair Loss

5 targets:

1. Hair breakage reduced after 1 application¹
2. Thicker, more resistant hair²
3. Helps promote stronger hair fibre³
4. Fortifies the scalp skin barrier through hydration
5. Soothes scalp discomfort due to dryness

¹Based on a combing breakage test.
²Instrumental test, after applications of Energising Fortifying Shampoo+ Fortifying Treatment
³Instrumental test, repeated application of the Energising Fortifying Shampoo + Fortifying Treatment

CLINICALLY PROVEN -29% HAIR LOSS* AFTER 6 WEEKS**

*Hair loss due to breakage.
**Clinical study conducted on Fortifying Treatment done on 86 subjects, 49 women and 37 men, after 6 weeks vs. baseline.

+26% VOLUME***

80% OF USERS SAW DECREASED HAIR BREAKAGE****

***Instrumental test after 1 application of tested products versus classic shampoo.
****Consumer test on Fortifying Treatment – Italy.

Expertise you can trust. Read the scientific publications supporting our dermatological solutions:

• A Canadian Consensus on Androgenetic Alopecia: Approach and Management
  Read More: https://doi.org/10.1177/12034754251368849

Androgenetic alopecia (AGA) is the most common hair loss condition affecting between 40% to 50% of Canadian men and women by 50 years of age. This nonscarring hereditary condition can significantly affect patients, impacting their overall well-being and quality of life. Despite the multitude of interventions and the willingness of people with AGA to try treatments, there are no clear Canadian guidelines on its management. An expert panel of 11 physicians developed Delphi-based consensus recommendations of interventions for the management of AGA in male and female adults. Forty-five interventions were reviewed. Seven interventions are recommended, including oral dutasteride; oral finasteride; topical finasteride; topical minoxidil; platelet-rich plasma; microneedling; and oral minoxidil. Five interventions are recommended with near consensus: intralesional dutasteride; ketoconazole shampoo; low level laser therapy; aminexil; as part of a regimen and 17 are not recommended (adenosine; cetirizine; carboxytherapy; amla syrup; microfilament thread; Nourkrin; injectable minoxidil; caffeine; ceramide; topical herbal formulations; piroctone olamine shampoo or leave-on; rosemary oil; shampoo and lotion hair care products containing fermented papaya, fermented mangosteen, and caffeine; basic Fibroblast Growth Factor (bFGF); flutamide).

• A Canadian Algorithm on the Management of Telogen Effluvium
  Read More: https://doi.org/10.1177/12034754251355198

Telogen effluvium (TE) is a form of transient hair loss in response to a triggering factor. It is a type of nonscarring alopecia, characterized by a generalized hair loss distribution with thinning of the hair and no exposed patches. It is thought to be induced by numerous stressors that cause hair follicles to suddenly switch from the growing (anagen) phase to the resting (telogen) phase. Treatment of TE consists of identifying the triggers and correcting them. TE is very common and affects men and women, with women being more emotionally and psychologically affected by the hair loss and seeking help more often. In the Canadian context, with long waiting lists to see a dermatologist, TE patients are often left alone with their worry and helplessness. This paper consolidates the opinions and recommendations of top Canadian hair-expert dermatologists with regards to TE management. Specifically, this consortium of experts identified the gap in care in Canada when it comes to TE and proposed a unified method to assess and manage TE. Their recommendations include making the proper diagnosis of TE, finding the triggers, which may include ordering appropriate investigations to identify metabolic abnormalities and nutritional deficiencies, and potentially managing treatable triggers of TE. Educating patients on TE is a crucial part of the treatment. The experts also concluded it is beneficial to offer patients a topical product that is safe and accessible.